Progenics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Progenics (US): 2 reconciled FDA prescription therapies, $8.0M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$8.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$8.0M
California HCAI SB 17 Filings1 WAC filings (max 16.8% 2-yr change)